Copyright Licensing Agency Licence Certificate 2023-24

This is to certify that The Copyright Licensing Agency Limited (“CLA”) has granted a Licence...

View document

MHRA Phase I Accreditation Certificate (October 2023)

The accreditation is based on the Unit continuing to maintain satisfactory standards for avoiding harm to trial subjects and for handling medical emergencies should they arise.

View document

MHRA Phase I Accreditation Certificate (01 June 2022)

The accreditation is based on the Unit continuing to maintain satisfactory standards for avoiding harm to trial subjects and for handling medical emergencies should they arise.

View document

MHRA Phase I Accreditation Certificate (August 2020)

MHRA Phase I Accreditation Certificate (August 2020)

View document

MHRA Phase I Accreditation Certificate (April 2017)

MHRA Phase I Accreditation Certificate (April 2017)

View document

MHRA Phase I Accreditation Certificate (March 2015)

MHRA Phase I Accreditation Certificate (March 2015)

View document

MHRA Phase I Accreditation Certificate (March 2013)

MHRA Phase I Accreditation Certificate (March 2013)

View document

Corporate Accounts 2021

Corporate Accounts 2021

View document

Corporate Accounts 2020

Corporate Accounts 2020

View document

Corporate Accounts 2019

Corporate Accounts 2019

View document

Corporate Accounts 2018

Corporate Accounts 2018

View document

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event